Overcoming everyday challenges in Alzheimer's Disease.*[1]

*Moderate to Severe Alzheimer's Disease.[2]

Meaningful Patient Benefits

- Maintains memory and language.[3]
- Maintains ability to perform everyday tasks such as eating, dressing and toileting.[1]
- Delays the emergence of agitation and aggression.[4]

Lundbeck

Ebixa®
memantine

Abbreviated Prescribing information: For full prescribing information refer to the Summary of Product Characteristics. **Name:** Ebixa® **Active Substance:** Memantine Hydrochloride. **Indication:** Treatment of patients with moderate to severe Alzheimer's Disease. **Dosage & Administration:** Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Therapy should only be started if a caregiver is available who will regularly monitor drug intake by the patient. Orally as tablets (10 mg) or solution (10 mg/g). Maintenance dose is 20mg, (10mg twice daily) taken with or without food. Treatment starts with 5mg (half a tablet or 10 drops) in the morning for a week; the 2nd week 5 mg (half a tablet or 10 drops) twice daily; the 3rd week 10mg (one tablet or 20 drops) in the morning and 5mg (half a tablet or 10 drops) in the afternoon or evening and the 4th week 10mg (one tablet or 20 drops) twice daily. Reduce the dose to 5mg (half a tablet or 10 drops) twice daily in patients with moderate renal impairment. Children & Adolescents: Not recommended. **Contraindications:** Hypersensitivity to the active substance or any of the excipients. **Pregnancy and Lactation:** Pregnancy: Memantine should not be used in pregnant women unless clearly necessary. Lactation: Memantine should not be used in women who are breastfeeding. **Special Warnings and Precautions for use:** Not recommended for patients with severe renal impairment. Caution is recommended in patients suffering from epilepsy. Caution is advised in patients with raised urine pH as this may elevate plasma levels. Clinical data are limited on patients with myocardial infarction, uncompensated congestive heart failure and uncontrolled hypertension and patients with these conditions should be closely supervised. Avoid concomitant use of NMDA antagonists e.g. amantadine, ketamine or dextromethorphan. Avoid use in patients with sugar intolerance. **Interactions:** Effects of L-Dopa, dopaminergic agonists and anticholinergics may be enhanced. Effects of barbiturates and neuroleptics may be reduced. Effect of concomitant treatment with antispasmodic agents e.g. dantrolene and baclofen may be modified. Plasma levels of cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine may be increased. Excretion may be altered when memantine and hydrochlorothiazide are co-administered. Concomitant use of NMDA antagonists-amantadine, ketamine or dextromethorphan should be avoided. Close monitoring of prothrombin time or INR is advisable for patients treated concomitantly with oral anticoagulants. **Adverse reactions:** Most commonly (>1/100 and <1/10) headache, somnolence, hypertension, constipation and dizziness. Uncommon reactions (>1/1000 and <1/100): fatigue, fungal infections, confusion, hallucinations, venous thrombosis/thromboembolism, vomiting, gait abnormal. Very rare (<1/10,000): seizures. Isolated cases of [illegible] psychotic reactions have been reported in post-marketing experience. Alzheimer's disease has been associated with depression, suicidal ideation and suicide. In post-marketing experience these events have been reported in patients treated with memantine. **Overdose:** Symptomatic treatment. **Elimination:** Mainly in unchanged form via the kidneys. **Administration:** Orally as tablets 10mg or solution 10mg/g. **Legal Category:** POM. **Marketing Authorisation Holder:** H.Lundbeck A/S, 9 Ottiliavej, DK-2500, Valby, Denmark. **Marketing Authorisation Numbers:** EU/1/02/219/005 Ebixa 10mg/g Oral drops solution-50g bottle. EU/1/02/219/006 Ebixa 10mg/g Oral drops solution-100g bottle. EU/1/02/219/007 Ebixa Tablets 10mg, 28 pack size. EU/1/02/219/008 Ebixa Tablets 10mg, 56 pack size. Further information may be obtained from: Lundbeck (Ireland) Ltd., 7 Riverwalk, Citywest Business Campus, Citywest, Dublin 24. **Date of Preparation:** March 2007. **References:** 1. Doody et al. Dement Geriatr Cogn Disord 2004; 18:227-232. 2. Ebixa Summary of Product Characteristics 2007. 3. Schmitt et al. Poster presented at AAGP 2005. 4. Gauthier et al. Int J Geriatr Psychiatry 2005; 20:459-64.

EB3/3/07

But now I can let life in."

This is the story of Sinead* and the voices she began hearing, they convinced her that her neighbours wanted her dead. So she barricaded herself in her tiny apartment for three years. Today, with the support of her doctor, treatment team and family, Sinead is managing her schizophrenia with Zyprexa.[1,2]

Knowing where you have been is one measure of how far you have come. Together you can find another way to stay on the road to improvement

 References 1: Tran PV et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. *J Clin Psychopharmacol* 1997;17:407-418. **2:** Kinon BJ, Hill AL, Lin L, Peralta DGS, Olanzapine orodispersible tablet in the treatment of acutely ill, non-compliant schizophrenia patients. Poster presented at American Psychiatric Association annual meeting, May 1-6 2004, New York, USA.

*Case study based on fictional characters

https://doi.org/10.1017/S0790966700010351 Published online by Cambridge University Press